Fixed-Duration Combinations, CLL17 Trial, and Triplet Therapy Considerations

Dr. Parikh summarizes the CLL17 trial: a 3-arm comparison of continuous ibrutinib, ibrutinib-venetoclax doublet, and venetoclax-obinutuzumab, all with approximately 3-year median follow-up showing no significant PFS difference between fixed-duration regimens and continuous ibrutinib. Although the ibrutinib comparator generates valid concerns about generalizability to current zanubrutinib/acalabrutinib practice, the key message affirms that fixed-duration regimens provide non-inferior PFS at this follow-up timepoint, giving clinicians strong latitude to recommend venetoclax-based combinations.

Dr. Lipsky cautions that 3 years represents "3 miles in a marathon". Interesting outcomes are expected at years 4 to 8 when long-term follow-up data mature. The panel broadly endorses BTK inhibitor-venetoclax oral doublets as reasonable for most frontline patients, noting that flexibility in BCL-2 inhibitor initiation timing (beyond the protocol-specified cycle 3 addition) allows venetoclax ramp-up to align with patients' TLS risk mitigation and scheduling needs.

Regarding triplet therapy (acalabrutinib-venetoclax-obinutuzumab), the panel reaches consensus that the AMPLIFY three-arm study showed PFS superiority for the triplet but inferior overall survival due to infection-related deaths, many COVID-related, raising significant concerns not fully resolved by censored analyses. The Alliance study demonstrated increased infectious mortality with ibrutinib-venetoclax-obinutuzumab in older patients, further limiting triplet enthusiasm.

The panel reserves triplet consideration for young, fit, high-risk patients with very specific circumstances (notably bulky disease where venetoclax-obinutuzumab isn't preferred), while emphasizing that treatment-related death is categorically unacceptable in CLL given that most patients die from unrelated causes.